Methods of treatment
AssigneeArena Pharmaceuticals, Inc.
InventorsChadwick J. Orevillo, Randall Kaye, Nuggehally Srinivas
Life of this patent
Estimating the term…
Abstract
Provided herein are treatment methods including administering a 5-hydroxytryptamine (HT)2C receptor agonist to a patient in need thereof. An exemplary method includes treating or preventing a 5-hydroxytryptamine (HT)2C receptor-associated disorder in a patient in need thereof, wherein the method comprises administering to the patient (R)—N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, wherein Compound 1, or a pharmaceutically acceptable salt thereof.
Claims19
1-4. (canceled)
A method of treating or preventing a seizure disorder in a patient in need thereof, wherein the method comprises administering to the patient (R)—N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof,
- wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to from about 0.03 to about 0.3 mg/kg Compound 1 free base three times daily (TID), provided that the individual has a body weight of ≤40 kg.
A method of treating or preventing developmental and epileptic encephalopathy (DEE) in a patient in need thereof, wherein the method comprises administering to the patient (R)—N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof,
- wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to from about 0.03 to about 0.3 mg/kg Compound 1 free base three times daily (TID), provided that the individual has a body weight of ≤40 kg.
A method of treating or preventing a refractory epilepsy in a patient in need thereof, wherein the method comprises administering to the patient (R)—N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to from about 0.03 to about 0.3 mg/kg Compound 1 free base three times daily (TID), provided that the individual has a body weight of ≤40 kg.
Dependencies are inferred from the claim text.